Transgene News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.06.25	Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders (GlobeNewswire)
21.12.23	Transgene Announces Upcoming Investor Meetings (Businesswire)
05.12.23	Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy (Businesswire)
07.11.23	Transgene Reports Business Update and Q3 2023 Financial Position (Businesswire)
10.10.23	Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab) (Businesswire)
20.09.23	Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024 (Businesswire)
14.09.23	Transgene Announces Upcoming Investor Meetings (Businesswire)
17.07.23	Transgene Receives $15.3 Million from the Sale of Securities Held for Sale (Businesswire)
06.06.23	Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023 (Businesswire)
05.06.23	Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023 (Businesswire)
25.05.23	Transgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors (Businesswire)
10.05.23	Transgene provides business update and Q1 2023 financial position (Businesswire)
10.05.23	Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer (Businesswire)
05.05.23	Transgene’s Combined General Meeting of May 5, 2023 (Businesswire)
05.05.23	Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio (Businesswire)
18.04.23	New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023 (Businesswire)
17.04.23	Transgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR (Businesswire)
12.04.23	Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director (Businesswire)
11.04.23	Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023 (Businesswire)
04.04.23	Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers (Businesswire)
27.03.23	Transgene Announces Upcoming Investor Meetings (Businesswire)
16.03.23	Transgene: 2022 Full-year Results and Business Update (Businesswire)
15.03.23	Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023 (Businesswire)
09.03.23	Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors (Businesswire)
06.01.23	Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration (Businesswire)
04.01.23	Transgene Announces Financial Calendar for 2023 (Businesswire)
15.12.22	Transgene Announces Upcoming Investor Meetings (Businesswire)
14.11.22	Transgene and BioInvent Joint Paper on BT-001 Wins JITC "Best Oncolytic and Local Immunotherapy Paper” Award for 2022 (Businesswire)
07.11.22	Transgene Reports Business Update And Q3 2022 Financial Position (Businesswire)
02.11.22	Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers (Businesswire)
27.09.22	R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data (Businesswire)
12.09.22	Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022 (Businesswire)
07.09.22	Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022 (Businesswire)
31.08.22	Transgene Announces Upcoming Investor Meetings (Businesswire)
28.06.22	Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA® (Businesswire)
27.06.22	Transgene and BioInvent Announce Positive Progress for BT-001 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Holcim	58.18	7.22 %	K V
Sika	219.80	3.58 %	K V
Logitech Intl	70.90	2.19 %	K V
UBS Group	25.50	2.00 %	K V
ABB	46.41	0.63 %	K V
Swiss Re	136.50	0.48 %	K V
Novartis	95.50	0.44 %	K V
Swisscom	570.00	0.35 %	K V
Givaudan	3’985.00	-0.18 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Transgene Aktie VALOR 862352 / ISIN FR0005175080

Nachrichten zu Transgene S.A.

Aktien Top/Flop

Meistgelesene Nachrichten